TY  - JOUR
T1  - Monosemptomatik enürezis nokturnası olan çocuklarda desmopressin tedavi sonuçlarını etkileyen faktörler
TT  - Factors influencing desmopressin treatment outcomes in children with monosymptomatic enuresis nocturna
AU  - Savun, Metin
AU  - Kalkanlı, Arif
AU  - Kandemir, Emre
AU  - Yanaral, Fatih
PY  - 2025
DA  - September
Y2  - 2025
JF  - Bozok Tıp Dergisi
PB  - Yozgat Bozok University
WT  - DergiPark
SN  - 2146-4006
SP  - 277
EP  - 282
VL  - 15
IS  - 3
LA  - tr
AB  - Amaç: Desmopressin monosemptomatik enürezis nokturna tedavisinde kullanılır. Ancak, desmopressin tedavisinin başarısını etkileyen faktörlere ilişkin veriler yetersizdir. Bu çalışma, monosemptomatik enürezis nokturnası olan çocuklarda desmopressin tedavisinin sonuçlarını etkileyen faktörleri değerlendirmeyi amaçlamaktadır. Gereç ve Yöntem: Bu çalışmaya, primer monosemptomatik enürezis nokturnası olan beş yaş üstü toplam 115 çocuk dahil edildi. Tüm hastalara günlük 120 mg desmopressin tedavisi uygulandı. Üç aylık tedaviden sonra hastalar iki gruba ayrıldı: 1. grup (başarılı) kuruluğa ulaşan çocukları içerirken, 2. grup (başarısız) tedaviye rağmen yatak ıslatmaya devam edenleri içeriyordu. Desmopressin tedavisinin başarısını etkileyen faktörler değerlendirildi. Bulgular: Ortalama anne yaşı, grup 1'de grup 2'ye kıyasla önemli ölçüde daha yüksekti (34,8'e karşı 32,4 yıl, p = 0,044). Haftada enüretik gece sayısı ve gece başına enürezis atakları Grup 2'de önemli ölçüde daha fazlaydı (6,8'e karşı 6 gece, p = 0,030; 1,7'ye karşı 1,4 atak, p = 0,040). Çok değişkenli analiz, 33 yaş üstü annelere sahip çocukların desmopressin tedavisine yanıt verme olasılığının 3,5 kat daha fazla olduğunu ortaya koydu (olasılık oranı: 3,5 [1,2-10,5], p = 0,023). Sonuç: Desmopressin tedavisinin başarısını etkileyen faktörler; anne yaşı, haftada enüretik gece sayısı ve gece başına enürezis sayısı olarak bulundu. Bunlar arasında, anne yaşı tedavi sonuçlarının tek bağımsız öngörücüsü olarak bulundu.
KW  - Deamino Arginin Vazopressin
KW  - Dezmopressin
KW  - enürezis
KW  - monosemptomatik gece idrar kaçırma
KW  - noktürnal enürezis
N2  - Aim: Desmopressin has been used in to treatment of monosymptomatic enuresis nocturna. However, data on the factors affecting desmopressin treatment success remain insufficient. This study aimed to evaluate the factors that influence desmopressin treatment outcomes in children with monosymptomatic enuresis nocturna. Material and Methods: A total of 115 children aged over five years with primary monosymptomatic enuresis nocturna were included in this study. All patients were treated with 120 mg desmopressin daily. After three months of treatment, the patients were divided into two groups: group 1 (successful) included children who achieved dryness, while group 2 (unsuccessful) comprised those who continued bedwetting despite treatment. Factors influencing the  success of desmopressin treatment were evaluated. Results: The mean maternal age was significantly higher in group 1 compared to group 2 (34.8 vs. 32.4 years, p = 0.044). The number of enuretic nights per week and enuresis episodes per night were significantly greater in Group 2 (6.8 vs. 6 nights, p = 0.030; 1.7 vs. 1.4 episodes, p = 0.040). Multivariate analysis revealed that children with mothers aged over 33 years were 3.5 times more likely to respond to desmopressin treatment (odds ratio: 3.5 [1.2-10.5], p = 0.023). Conclusion: Factors influencing desmopressin treatment success included maternal age, frequency of enuretic nights per week, and the number of enuresis episodes per night. Among these, maternal age was identified as the only independent predictor of treatment outcomes.
CR  - 1. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P et al.
The standardization of terminology of lower urinary tract function in
children and adolescents: Update report from the standardization
committee of the International Children's Continence Society.
Neurourol Urodyn. 2016;35(4):471-81.
CR  - 2. The ICD-10 classification of mental and behavioral disorders
in children and adolescents: ISBN 92-4-154422-8. World Health
Organization, Geneva, Switzerland. 2008;38-9
CR  - 3. Sharma N, Mishra R, Mishra D. The fifth edition of Diagnostic and
Statistical Manual of Mental Disorders (DSM-5): what is new for the
pediatrician? Indian Pediatr. 2015;52(2):141-3.
CR  - 4. Arda E, Cakiroglu B, Thomas DT. Primary nocturnal enuresis: a
review. Nephro-urology monthly 2016;8(4),1-6.
CR  - 5. Deshpande AV, Caldwell PH. Medical management of nocturnal
enuresis. Pediatr drugs 2012;14(2),71-7.
CR  - 6. Walker RA. Nocturnal Enuresis. Prim Care 2019;46(2),243-8.
CR  - 7. Jain S, Bhatt GC. Advances in the management of primary
monosymptomatic nocturnal enuresis in children. Paediatr Int Child
H 2016;36(1),7-14.
CR  - 8. Song P, Huang C, Wang Y, Wang Q, Zhu W, Yue Y et al. Comparison
of desmopressin, alarm, desmopressin plus alarm, and desmopressin
plus anticholinergic agents in the management of paediatric
monosymptomatic nocturnal enuresis: a network meta-analysis. BJU
Int. 2019;123(3):388-400.
CR  - 9. Kamperis K, Van Herzeele C, Rittig S, Walle JV. Optimizing response
to desmopressin in patients with monosymptomatic nocturnal
enuresis. Pediatr Nephrol, 2017;32(2), 217-26.
CR  - 10. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate:
study of 1129 enuretics. Arch Dis Child 1974;49:259–63.
CR  - 11. Van Herzeele C, Evans J, Eggert P, Lottmann H, Norgaard JP, Walle
JV. Predictive parameters of response to desmopressin in primary
nocturnal enuresis. J Ped Urol, 2015;11(4),200-e1.
CR  - 12. Montaldo P, Tafuro L, Rea M, Narciso V, Iossa AC, Gado RD.
Desmopressin and oxybutynin in monosymptomatic nocturnal
enuresis: a randomized, double blind, placebo controlled trial and
an assessment of predictive factors. BJU Int 2012;110(8b), E381-6.
CR  - 13. Kruse S, Hellstrom AL, Hanson E, Hjälmås K, Sillén U. Swedish
Enuresis Trial (SWEET) Group Treatment of primary mono
symptomatic nocturnal enuresis with desmopressin: predictive
factors. Br J Urol 2001;88(6):572–6
CR  - 14. Yanaral F, Eroğlu A, Çilesiz NC, Gezmiş CT, Tandoğdu Z, Balcı
MBC et al. Evaluation of Etiological Risk Factors of Primary
Monosymptomatic Enuresis. J Acad Res Med 2019;9(3),102-6.
CR  - 15. Järvelin MR, Vikeväinen-Tervonen L, Moilanen I, Huttunen NP.
Enuresis in seven-year-old children. Acta Paediatr Scand 1988;77(8):
148–53.
CR  - 16. Tai TT, Tai BT, Chang YJ, Huang KH. The Importance of
Understanding Parental Perception When Treating Primary
Nocturnal Enuresis: A Topic Review and an Institutional Experience.
Res Rep Urol. 2021;13:679-90.
CR  - 17. Yitik Tonkaz G, Deliağa H, Çakir A, Tonkaz G, Özyurt G. An
evaluation of parental attitudes and attachment in children with
primary monosymptomatic nocturnal enuresis: A case-control study.
J Pediatr Urol. 2023;19(2):174.e1-5.
CR  - 18. Schlomer B, Rodriguez E, Weiss D, Copp H. Parental beliefs
about nocturnal enuresis causes, treatments, and the need to seek
professional medical care. J Pediatr Urol. 2013;9(6 Pt B):1043-8.
CR  - 19. Onol FF, Guzel R, Tahra A, Kaya C, Boylu U. Comparison of longterm efficacy of desmopressin lyophilisate and enuretic alarm for
monosymptomatic enuresis and assessment of predictive factors for
success: a randomized prospective trial. J Urol 2015;193(2), 655-61.
CR  - 20. Sancak EB, Oguz U, Aykac A, Demirelli E, Bozkurt OF, Cimen S. The
effect of breastfeeding on spontan resolution of monosymptomatic
enuresis. Int Braz J Urol, 2016;42(3),550-7.
UR  - https://dergipark.org.tr/en/pub/bozoktip/issue//1660532
L1  - https://dergipark.org.tr/en/download/article-file/4702656
ER  -